S100B is not a reliable prognostic index in paediatric TBI.

Department of Anaesthesia and Intensive Care, University of Naples Federico II, Naples, Italy.
Pediatric Neurosurgery (Impact Factor: 0.42). 02/2007; 43(4):258-64. DOI: 10.1159/000103304
Source: PubMed

ABSTRACT As far as paediatric traumatic brain injury is concerned, it is difficult to quantify the extent of the primary insult, to monitor secondary changes and to predict neurological outcomes by means of the currently used diagnostic tools: physical examination, Glasgow Coma Scale (GCS) score and computed tomography. For this reason, several papers focused on the use of biochemical markers (S100B, neuron-specific enolase) to detect and define the severity of brain damage and predict outcome after traumatic head injury or cardiac arrest.
The aim of this paper is measuring the range of S100B serum concentrations in children affected by traumatic brain injury and describing the possible roles of this protein in the reaction to trauma.
Fifteen children aged 1-15 years were included in the study. Traumatic brain injury severity was defined by paediatric GCS score as mild (9 patients), moderate (2 patients) or severe (4 patients). Blood samples for S100B serum measurement were taken at emergency department admission and after 48 h.
The serum S100B concentration was higher in the group of severe trauma patients, who scored the lowest on the GCS at admission, and among them, the highest values were reported by the children with concomitant peripheral lesions.
The role of S100B in paediatric traumatic brain injury has not been clarified yet, and the interpretation of its increase when the head trauma is associated with other injuries needs the understanding of the physiopathological mechanisms that rule its release in the systemic circulation. The levels of S100B in serum after a brain injury could be related to the mechanical discharge from a destroyed blood-brain barrier, or they could be due to the active expression by the brain, as a part of its involvement in the systemic inflammatory reaction. Early increase of this protein is not a reliable prognostic index of neurological outcome after pediatric traumatic brain injury, since even very elevated values are compatible with a complete neurological recovery.

  • [Show abstract] [Hide abstract]
    ABSTRACT: During the past decade there has been an increasing recognition of the incidence of mild traumatic brain injury (mTBI) and a better understanding of the subtle neurological and cognitive deficits that may result from it. A substantial, albeit suboptimal, effort has been made to define diagnostic criteria for mTBI and improve diagnostic accuracy. Thus, biomarkers that can accurately and objectively detect brain injury after mTBI and, ideally, aid in clinical management are needed. In this review, we discuss the current research on serum biomarkers for mTBI including their rationale and diagnostic performances. Sensitive and specific biomarkers reflecting brain injury can provide important information regarding TBI pathophysiology and serve as candidate markers for predicting abnormal computed tomography findings and/or the development of residual deficits in patients who sustain an mTBI. We also outline the roles of biomarkers in settings of specific interest including pediatric TBI, sports concussions and military injuries, and provide perspectives on the validation of such markers for use in the clinic. Finally, emerging proteomics-based strategies for identifying novel markers will be discussed.
    Medicinal Research Reviews 06/2013; · 9.58 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Primary objective: To identify which tool (a model, a biomarker or a combination of these) has better prognostic strength in traumatic brain injury (TBI). Design and methods: Data of 100 patients were analysed. TBI prognostic model B, constructed in Trauma Audit and Research Network (TARN), was run on the dataset and then S100B was added to this model. Another model was developed containing only S100B and, subsequently, other important predictors were added to assess the enhancement of the predictive power. The outcome measures were survival and favourable outcome. Results: No difference between performance of the prognostic model or S100B in isolation is observed. Addition of S100B to the prognostic model improves the performance (e.g. AUC, R(2) Nagelkerke and classification accuracy of TARN model B to predict survival increase respectively from 0.66, 0.11 and 70% to 0.77, 0.25 and 75%). Similarly, the predictive power of S100B increases by adding other predictors (e.g. AUC (0.69 vs. 0.79), R(2) Nagelkerke (0.15 vs. 0.30) and classification accuracy (73% vs. 77%) for survival prediction). Conclusion: A better prognostic tool than those currently available may be a combination of clinical predictors with a biomarker.
    Brain Injury 03/2014; · 1.51 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The current diagnostic criteria for traumatic brain injury (TBI) are heavily reliant on an accurate clinical history of events. Diagnosis of mild injury relies on one or more of the following: confusion or disorientation, loss of consciousness (LOC) for 30 min or less, post-ictus amnesia for less than 24 h and/or other transient neurological abnormalities and a Glasgow Coma Score (GCS). Given the nature of the condition it is obvious that significant clinical challenges remain to identify in the cases of mild TBI, and additionally to grade more severe forms so that appropriate treatment is received. The lack of clinically useful biomarkers in the serum of TBI patients is a significant barrier to improving their outlook. Discovery of such markers would aid the timely diagnosis of novel and recurrent disease in a minimally invasive manner. A PubMed search was performed to identify studies reporting serum biomarkers in traumatic brain injury. Details regarding the biomarkers analysed, specificity, indications for outcome and statistical significance were recorded. A total of 40 manuscripts reporting 11 biomarkers were identified in the literature. All but a few studies reported statistically significant differences in biomarker expression between groups. We conclude that serum biomarkers of TBI are an effective means for investigating the condition. However, the lack of novel markers identified in this mass of studies highlights the need to adopt new measure of biomarker identification.
    British Journal of Neurosurgery 07/2013; · 0.86 Impact Factor